Generic Name and Formulations:
Lidocaine 7%, tetracaine 7%; emulsion cream.
Indications for PLIAGLIS:
Local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, laser-assisted tattoo removal).
Do not exceed recommended dose or duration. Apply to intact skin prior to procedure; spread evenly and thinly across treatment area using a metal spatula or tongue depressor. Dermal filler inj or facial laser ablation: apply for 20–30 mins. Laser-assisted tattoo removal: apply for 60 mins. Amount (length) to apply: see full labeling.
Avoid overexposure. History of congenital or idiopathic methemoglobinemia: not recommended. G6PD deficiency. Severe hepatic impairment. Pseudocholinesterase deficiency. Avoid contact with eyes, mucous membranes, or areas with a compromised skin barrier (eg, broken or inflamed). Risks of secondary exposure to children and pets; may be toxic. Acutely ill. Debilitated. Elderly. Pregnancy (Cat.B). Nursing mothers.
Toxicity may be potentiated by Class I antiarrhythmics (eg, tocainide, mexiletine); caution. Additive effects with other local anesthetics; consider the amount absorbed from all formulations. Increased risk of methemoglobinemia with concomitant methemoglobin-inducing agents (eg, sulfonamides, acetaminophen, acetanilide, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, p- aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, and quinine).
Topical anesthetic (amide-type + ester-type).
Localized reactions (eg, erythema, skin discoloration, edema), allergic reactions (eg, urticaria, angioedema, bronchospasm, shock).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma